Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's episode of Five Must-Know Things: large M&A deals under regulatory review; surprise at Roche’s cardiovascular deal; BioNTech’s multiple China partnerships; GSK preps for US RSV vaccine launch; and a look at the dynamic multiple myeloma market.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 28 July 2023, including: large M&A deals under regulatory review; surprise at Roche Holding AG’s cardiovascular deal; BioNTech SE’s multiple China partnerships; GSK plc preps for US RSV vaccine launch; and a look at the dynamic multiple myeloma market.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Reading The FTC Tea Leaves: Investors Await Insights For M&A" - Scrip, 26 Jul, 2023.)
(Also see "Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam" - Scrip, 24 Jul, 2023.)
(Also see "Can BioNTech Take China Early-Stage Biotech Innovation Global?" - Scrip, 26 Jul, 2023.)
(Also see "GSK Confirms Arexvy Price And US Contract Negotiations Ahead Of Launch" - Scrip, 26 Jul, 2023.)
(Also see "Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves" - Scrip, 26 Jul, 2023.)